gland pharma glp-1 capacity reported a strong December quarter with 22.5% revenue growth and 27% YoY profit growth, driven by healthy performance across the US, India, and Europe. The stock reacted positively, gaining over gland pharma glp-1 manufacturing capacity

Options include bioelectrical impedance scales, DEXA scans, or a simple tape measure to assess nonscale changes

60% of respondents have made a lifestyle change (with or without GLP-1s)

The estimates that Novos CEO put out is that there are approximately 1.5 million people using compounded drugs, primarily semaglutide

For instance, Cigna reported a trailing price-to-earnings ratio around 9.1 as referenced by GuruFocus on 06/03/2026, which can be compared with higher multiples often seen at larger diversified peers such as UnitedHealth Group, while Cigna's 52-week trading range from about USD 239.51 to USD 338.89 shows that its current level near USD 272 is below both that recent high and some consensus price targets in the sector as compiled by certain analyst aggregators